You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 12,239,739

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,239,739

Title:	Oral dosing of GLP-1 compounds
Abstract:	The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.
Inventor(s):	Flemming S. Nielsen, Per Sauerberg
Assignee:	Novo Nordisk AS
Application Number:	US16/361,971
Patent Claims:	1. A method for treating type 2 diabetes and/or reducing body weight in a subject in need of such treatment, the method comprising: orally administering to the subject a therapeutically effective amount of a solid oral dosage form composition comprising a glucagon-like peptide-1 (GLP-1) peptide and an enhancer, wherein: (a) the GLP-1 peptide is N-epsilon26-[2-(2-{2-[2-(2-{2- [(S)-4-Carboxy-4-(17-carboxyheptadecanoyl-amino) butyrylamino] ethoxy} ethoxy) acetylamino] ethoxy} ethoxy) acetyl] [Aib8,Arg34] GLP-1-(7-37) (semaglutide); and (b) the enhancer is sodium N-(8-(2-hydroxybenzoyl) amino) caprylate (SNAC); wherein semaglutide is the only GLP-1 peptide administered; wherein the composition is administered daily for a period of 70 days; and wherein the variability in plasma exposure of said GLP-1 peptide is reduced when compared to a single dose of the GLP-1 peptide. 2. The method according to claim 1, wherein the subject is in need of treatment for both type 2 diabetes and reducing body weight. 3. The method according to claim 2, wherein the composition comprises 200-400 mg of the SNAC. 4. The method according to claim 2, wherein the composition comprises 2-40 mg of the semaglutide. 5. The method according to claim 4, wherein the composition comprises 300 mg of the SNAC. 6. The method according to claim 2, wherein the composition comprises 5-50 mg of the semaglutide. 7. The method according to claim 6, wherein the composition comprises 300 mg of the SNAC. 8. The method according to claim 2, wherein the composition is in the form of a tablet. 9. The method according to claim 2, wherein the subject suffers from obesity. 10. The method according to claim 1, wherein the subject is in need of treatment for type 2 diabetes. 11. The method according to claim 10, wherein the composition comprises 200-400 mg of the SNAC. 12. The method according to claim 10, wherein the composition comprises 2-40 mg of the semaglutide. 13. The method according to claim 12, wherein the composition comprises 300 mg of the SNAC. 14. The method according to claim 13, wherein the composition is in the form of a tablet. 15. The method according to claim 10, wherein the composition comprises 5-50 mg of the semaglutide. 16. The method according to claim 15, wherein the composition comprises 300 mg of the SNAC. 17. The method according to claim 16, wherein the composition is in the form of a tablet. 18. The method according to claim 1, wherein the patient is in need of treatment for reducing body weight. 19. The method according to claim 18, wherein the composition comprises 200-400 mg of the SNAC. 20. The method according to claim 18, wherein the composition comprises 2-40 mg of the semaglutide. 21. The method according to claim 20, wherein the composition comprises 300 mg of the SNAC. 22. The method according to claim 21, wherein the subject suffers from obesity. 23. The method according to claim 21, wherein the composition is in the form of a tablet. 24. The method according to claim 18, wherein the composition comprises 5-50 mg of the semaglutide. 25. The method according to claim 24, wherein the composition comprises 300 mg of the SNAC. 26. The method according to claim 25, wherein the subject suffers from obesity. 27. The method according to claim 25, wherein the composition is in the form of a tablet.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.